Survival and causes of death in 366 Hungarian patients with systemic sclerosis

Ann Rheum Dis. 2008 Jan;67(1):59-63. doi: 10.1136/ard.2006.066340. Epub 2007 May 22.

Abstract

Objective: Survival analysis of a series of 366 consecutive patients with systemic sclerosis (SSc).

Methods: Clinical and laboratory data were evaluated from 1983 until 2005 using a standard protocol. The female/male ratio was 315/51. The mean (SD) age of the patients was 56.8 (12.2) years. The duration of disease was 12 (5-19) years with a median follow-up of 6 (3-12) years.

Results: Kaplan-Meier univariate analysis showed that renal, cardiac involvement, pigmentation disturbances, malabsorption, a forced vital capacity <50%, diffuse scleroderma, presence of early malignancy, anaemia, and increased erythrocyte sedimentation rate (ESR) were signs of unfavourable prognosis, whereas anti-centromere antibodies were indicators of a good survival. In the multivariate Cox proportional hazards model the presence of diffuse scleroderma, renal involvement, coexistence of a malignant disease, and increased ESR were poor independent prognostic signs. Elderly age at the onset of disease also caused an unfavourable outcome. A total of 86 SSc-related deaths were recorded during the follow-up. Of them, 65% were attributed to cardiorespiratory manifestation of disease. Tumour associated early death was found in 12 cases (14%).

Conclusions: In addition to the well-known factors influencing the outcome (diffuse subset, internal organ involvements, and inflammatory signs), the coexistence of scleroderma with a malignancy also causes a poor outcome.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Age Factors
  • Aged
  • Autoantibodies / blood
  • Blood Sedimentation
  • Cause of Death
  • Centromere / immunology
  • Female
  • Heart Diseases / complications
  • Heart Diseases / mortality
  • Humans
  • Kidney Diseases / complications
  • Kidney Diseases / mortality
  • Male
  • Middle Aged
  • Neoplasms / complications
  • Neoplasms / mortality
  • Prognosis
  • Proportional Hazards Models
  • Prospective Studies
  • Scleroderma, Diffuse / complications
  • Scleroderma, Diffuse / mortality
  • Scleroderma, Systemic / complications
  • Scleroderma, Systemic / immunology
  • Scleroderma, Systemic / mortality*
  • Survival Analysis

Substances

  • Autoantibodies